7:25-7:30 am Regenerative Strategies Sheldon S. Lin, MD Newark, New Jersey
|
|
- Matthew Park
- 5 years ago
- Views:
Transcription
1 7:25-7:30 am Regenerative Strategies Sheldon S. Lin, MD Newark, New Jersey INTRODUCTION For years, mechanical stabilization has played a fundamental role in the successful management of foot and ankle trauma and elective surgeries. However, a multitude of risk factors have been shown to cause impaired osseous healing and delayed soft tissue regeneration, resulting in poor clinical outcomes in certain patient populations. In an effort to address this concern, research over the past decade has led to the exploration of numerous growth factors, namely platelet-rich plasma (PRP), bone morphogenetic proteins (BMPs), and recombinant human platelet-derived growth factor (rhpdgf), which may serve as potential biologic adjuncts to conventional therapy by promoting bone and soft-tissue healing. PLATELET-RICH PLASMA Platelet rich plasma (PRP) is a bioactive component derived from autologous blood that contains a concentrated volume of platelets, typically a 5-fold increase (~1,000,000/ l) above physi When activated, platelets within the concentrate release a number of growth factors that have been shown to set the stage for healing and regeneration of musculoskeletal tissues. These growth factors include platelet-derived growth factor (PDGF), transforming growth factor (TGF), insulin-like growth factor (IGF), vascular endothelial growth factor (VEGF), and epidermal growth factor (EGF). Their role(s) in the various stages of osseous and soft-tissue healing, including hematoma formation, chemotaxis of inflammatory cells, proliferation and differentiation of mesenchymal cells, remodeling, angiogenesis, and extracellular matrix formation, have been well-described(gandhi, Bibbo et al. 2005; Alsousou, Thompson et al. 2009) Several PRP preparation systems are currently available(dohan Ehrenfest, Rasmusson et al. 2009). While no accepted standard for the preparation of PRP exists, the basic process consists of a two-step centrifugation of autologous, anticoagulated blood to first obtain plasma, followed by isolation of a plateletrich concentrate(foster, Puskas et al. 2009). Additionally, some investigators choose to activate PRP with thrombin in an effort to provide an immediate high-dose delivery of the various growth factors to the site of application. Each preparation system delivers varying final platelet and growth factor concentrations(dohan Ehrenfest, Rasmusson et al. 2009). PRP was first clinically applied in oral and maxillofacial surgery in the 1990s, where initial studies provided support for its use as an osteoconductive agent(tayapongsak, O'Brien et al. 1994; Marx, Carlson et al. 1998). In plastic surgery and other surgical subspecialties, applications for the use of PRP were in the realm of hemostasis and wound healing to improve postoperative prognosis with respect to infection, blood loss, and pain(delrossi, Cernaianu et al. 1990; Eppley, Pietrzak et al. 2006). Over the past decade, orthopaedic surgeons have used PRP as a bioadjuvant to improve bone healing in spinal fusion, fracture repair, and limb lengthening procedures(lowery, Kulkarni et al. 1999; Dallari, Savarino et al. 2007; Kitoh, Kitakoji et al. 2007; Kitoh, Kitakoji et al. 2007). More recently, the utility of PRP in sports medicine as a safe bioadjuvant to accelerate tendinous healing has been shown(hall, Band et al. 2009; Mishra, Woodall et al. 2009). However, only limited data are currently available that definitively describes the role of the clinical application of PRP in foot and ankle surgery. Several investigators have proposed that PRP can serve as a safe adjunct, when applied locally; especially in high-risk patients who demonstrate risk factors for impaired bone healing. Review of Literature:Bibbo and colleagues(bibbo, Bono et al. 2005) published the first evidence-based study demonstrating the use of PRP in high-risk patients undergoing elective foot and ankle surgery. In this prospective observational study, 62 high-risk patients (encompassing 123 operative procedures) were followed for a period of 6 months after receiving PRP applied locally to the surgical site. At least 1 risk factor for poor or delayed osseous healing (as listed in TABLE) was identified in all patients. Patients demonstrated various pathologies involving the hindfoot, forefoot, or ankle for which they underwent 32
2 operative fixation, as appropriately determined by the surgeon. Additionally, some patients received bone graft in combination with PRP if it was required to fill a bony defect or in order to correct alignment (e.g. lateral column lengthening). Evaluation for radiographic union was performed every 2 weeks. The clinical outcomes and complications associated with the local application of PRP were assessed. Overall, a 94% union rate was achieved at a mean of 41 days. The mean time to union for patients treated with PRP alone was 40 days, versus 45 days for patients that received bone graft in combination with PRP. The investigators concluded that the adjunctive use of PRP is an important tool in high-risk elective foot and ankle surgery with or without the use of bone graft, resulting in an acceptable time to union with low risk for complications. However, due to the varying pathologies, inconsistent surgical technique, and absence of a control group, the efficacy of the local application of PRP cannot be directly determined from this study. In 2005, Barrow and Pomeroy(Barrow and Pomeroy 2005), and later, Coetzee and colleagues(coetzee, Pomeroy et al. 2005), demonstrated that PRP reduced the time to union in ankle syndesmotic fusions in total ankle replacement (TAR), which is a critical next step required before patients can proceed with advanced weight bearing status and the overall success of the Agility TAR (Depuy, Inc, Warsaw, IN). Barrow and Pomeroy(Barrow and Pomeroy 2005) investigated the effect of PRP-augmented bone grafting on syndesmotic fusion rates in 20 consecutive patients undergoing Agility TAR for post-traumatic arthritis, rheumatoid arthritis, or osteoarthritis. Prior to surgery, at least 6 months of conservative management (i.e. bracing) was attempted. The operative technique for the Agility TAR as described by Alvine was employed with some modifications(alvine 2002). Symphony PCS autologous platelet concentrate (Depuy Corp, Warsaw, Indiana) was sprayed on the bone surfaces of the syndesmosis, the cut surfaces of the distal tibia and talus, and over the porous coating of the ankle prosthesis. PRP was also mixed with local autograft derived from resected bone, which was packed in the distal tibiofibular joint after insertion of the TAR components. The investigators reported successful fusion of the syndesmosis in all 20 cases within 6 months; 85% at 2 months, 95% at 3 months, and 100% at 6 months. This was compared to previously reported distal tibiofibular joint fusion rates of 62-82% at 6 months(pyevich, Saltzman et al. 1998; Saltzman and Alvine 2002). Similarly, in a preliminary study by Coetzee and colleagues(coetzee, Pomeroy et al. 2005), PRP was used to promote syndesmotic fusion in patients undergoing TAR. The investigators compared fusion rates in 66 patients using PRP augmented bone grafting versus 114 patients as historical controls with non-prp augmented bone grafting of the ankle syndesmosis performed during TAR. The operative technique was similar to that used by Barrow and Pomeroy(Barrow and Pomeroy 2005). Patients were followed to assess radiographic union, which was evaluated by standard ankle radiographs or with computed tomography (CT) scans if there was questionable radiographic evidence of a syndesmotic fusion. The results of this study showed statistically significant improvement in 8- and 12-week fusion rates from 61.4% and 73.6% respectively, in historical controls (n=114), to 76% and 93.9% respectively, in patients with PRPaugmented bone grafting (n=66). Additionally, a significant reduction in delayed unions and nonunions at 6 months with the addition of PRP was observed. Dallari and colleagues(dallari, Savarino et al. 2007) demonstrated that the supplementation of locally implanted allograft bone chips with bone marrow aspirate containing pluripotential stromal cells, in combination with PRP significantly enhanced healing rates in patients undergoing tibial osteotomy. This concept was further explored by Pinzur(Pinzur 2009) *, who studied the effects of PRP and bone marrow aspirate in high-risk patients with Charcot arthropathy of the foot. In this prospective case series, 44 diabetic patients (46 feet) at high risk (immunodeficient, morbidly obese, osteomyelitis at deformity site, or demonstrating multiple diabetic co-morbidities) for unfavorable clinical results with conventional surgery underwent surgical correction for their deformity. A static external fixator was applied to maintain postoperative surgical correction. Prior to wound closure, freshly-prepared PRP and bone marrow aspirate were injected locally into the fusion site. After partial weight-bearing for 8 weeks, the external fixator was removed, and a total contact cast was placed for 4 to 6 weeks. Serial radiographs were obtained to evaluate osseous healing. In spite of having risk factors for delayed or impaired bone healing, 91.3% (n=46) of all fusion sites showed radiographic evidence of osseous union at 16 weeks after surgery, 33
3 and clinically acceptable results were also observed, as evident by patients ability to ambulate using commercially available therapeutic footwear. BONE MORPHOGENETIC PROTEINS Bone morphogenetic proteins are the key modulators of osteoprogenitor and mesenchymal cells during osseous healing. With more than 20 BMPs identified so far, all but BMP-1, belong to the Transforming Growth Factor beta super family of proteins and have regulatory effects in the differentiation and proliferation of cartilage and bone-forming cells from pleuripotent mesenchymal stem cells during the process of bone healing(reddi 1994). BMPs interact with specific receptors on the cell surface, referred to as bone morphogenetic protein receptors (BMPRs) which are heteromeric complexes of type 1 and type 2 serine/threonine kinase receptors. Binding of BMPs to the receptor complex results in the phosphorylation of intracellular SMAD proteins which then translocates to the nucleus, where they regulate transcription(shi and Massague 2003). SMAD proteins are a family of proteins that are involved in the translocation of signals from TGFbeta receptors; bone morphogenetic protein receptors; and other surface receptors to the cell nucleus. BMPs induce new bone formation by way of endochondral ossification and in high concentration can even form new bone by intramembranous ossification(wozney 1993). Several BMPs, like BMP 2, 4 and 7 are shown to have prominent roles in bone formation(lieberman, Daluiski et al. 2002). BMP-4 mrna is reported to be up-regulated at the fracture site as early as 12 hours and BMP-2 and BMP-4 protein concentrations have been shown to be elevated as early as 2 days following fracture(nakase, Nomura et al. 1994; Bostrom, Lane et al. 1995; Yoshimura, Nomura et al. 2001). Further, BMP 2 and 4 drive osteoprogenitor cells to mature into osteoblasts(onishi, Ishidou et al. 1998). Finally, BMP 3a, 4 and 7 show increased concentration in the osteogenic phase when bone maturation commences(bostrom, Lane et al. 1995; Ishidou, Kitajima et al. 1995; Cho, Gerstenfeld et al. 2002). As the precursor cells mature and callus remodels, BMP 2 expression decreases(bostrom and Asnis 1998). Genetic engineering techniques have enabled production of growth factors, like recombinant human bone morphogenetic proteins (rhbmps) for both experimental and clinical uses. Currently, only rhbmp-2 and rhbmp-7 are commercially available, after having been approved by FDA for clinical use in open tibia fracture and posterior lumbar fusion and as humanitarian device exemption for failed treated tibia non-unions, respectively(axelrad and Einhorn 2009) **. Review of Literature Clinical studies have recently reported on the successful use of rhbmp-2 in complex ankle and hindfoot arthrodesis. In a prospective study, Bibbo and Haskell(Bibbo 2007) utilized rhbmp-2 (Infuse) in complex ankle and hindfoot fusions. In 45 procedures, the authors reported the mean time of union of 10 weeks (range 4-30 weeks) and wound issues in only 2 patients. In a more recent follow-up of their original series, Bibbo and colleagues(bibbo, Patel et al. 2009) * retrospectively analyzed the use of rhbmp-2 in a total of 112 high-risk ankle and hindfoot fusions in 69 patients. These patients were categorized as highrisk based upon risk-factors for poor bone healing including diabetes mellitus, high-energy injury, and immunosuppression. Overall, 108 of 112 fusion sites underwent union in these high-risk patients with a mean time of union of 11 weeks, with no significant difference in union-rates seen amongst the different sites of fusion. Wound complications were seen in only 3 patients, which were successfully treated with local wound care and antibiotics. PLATELET-DERIVED GROWTH FACTOR Platelet-derived growth factor (PDGF) is a family of growth factors released from platelets and macrophages in response to tissue injury that form a series of disulfide-linked dimers including PDGF-AA, AB, BB, CC, and DD(Alvarez, Kantarjian et al. 2006). PDGF has been shown to promote the synthesis and release of several other growth factors, and to stimulate various mesenchymal-derived cells to further enhance DNA synthesis, augment collagen deposition, and increase synthesis of extracellular matrix(hollinger, Hart et al. 2008) **. PDGF-BB is the most potent among the prevalent circulating isoforms. As a consequence of these biologic properties, the therapeutic potential of recombinant human PDGF-BB 34
4 (rhpdgf-bb) has been a focus of recent interest in orthopaedic surgery, among other surgical subspecialties. Although its utility in the clinical arena has not been well-described in orthopaedic literature, several recent scientific studies highlight the future potential of rhpdgf-bb in foot and ankle surgery. Review of Literature Hollinger and colleagues(hollinger, Onikepe et al. 2008) used a tibial osteotomy model to study the effect of locally delivered rhpdgf-bb (in 20mM sodium acetate buffer or acetate buffer alone) in combination with ß-tricalcium phosphate (ß-TCP) and collagen matrix in geriatric, osteoporotic ovariectomized female rats. Mechanical testing at 5 weeks demonstrated no statistical difference in torsional strength of fractured tibiae treated with rhpdgf-bb versus the non-fractured contralateral tibiae, while non-rhpdgf-bb treated groups showed significant reduction in torsional strength. Histological analysis at the same timepoint indicated accelerated callus formation in the rhpdgf-bb treated group. Al- Zube and colleagues(al-zube, Breitbart et al. 2009) * demonstrated similar results with the use of rhpdgf with ß-TCP and collagen matrix in a femur fracture model using diabetic BB Wistar rats. Upon local application at the fracture site, rhpdgf-bb was shown to increase cellular proliferation at Day 4, enhance biomechanical callus properties (i.e. torsional strength) at Week 8, and increase bony bridging as evident on histomorphometric analysis at Week 12 post-fracture, in a dose-dependent manner. The investigators(hollinger, Onikepe et al. 2008; Al-Zube, Breitbart et al. 2009) concluded that rhpdgf-bb significantly enhanced bone healing in their osteoporotic and diabetic animal models, respectively, and may prove beneficial in orthopaedic applications for patients at risk for impaired osseous healing. Summary for Growth Factor Despite ongoing advances in orthopaedics, reconstructive surgery of the foot and ankle continues to be a challenging endeavor. This is especially true when operating on high-risk patients with compromised musculoskeletal-healing ability, for which PRP, BMPs, and rhpdgf-bb may contribute significantly to achieve more favorable clinical outcomes, reduce complication rates, and improve patient satisfaction. While there is ample scientific research that demonstrates the potential role of the described bioadjuvants on bone and soft tissue healing, further clinical investigation by way of prospective randomized studies is needed to establish safety, determine efficacy, and define ideal patient populations that can benefit from the use of these orthobiologics. Only then can their routine application in foot and ankle surgical interventions be considered and widely accepted. BIOPHYSICAL STIMULATION Several options are currently available for clinicians to promote the healing of fractures and accelerate the rate of union in elective arthrodesis, including the utility of biophysical stimulators, namely low intensity pulsed ultrasonography (LIPUS) and electrical bone stimulation devices such as pulsed electromagnetic field (PEMF) and direct current (DC). A Canadian survey of 450 trauma surgeons, with a response rate 60%, found that 45% of surgeons reported using bone stimulators to manage tibial fractures, with their use evenly divided between LIPUS and PEMF therapy(busse, Morton et al. 2008). We plan to review the specific literature of the use of LIPUS and PEMF in the field of foot and ankle, with a focus in DM patients. Low-intensity Pulsed Ultrasonography The Food and Drug Administration approved the use of LIPUS for acceleration of healing of conservatively managed fresh fracture healing in 1994, and for treatment of established nonunions in 2000(Rubin, Bolander et al. 2001). In vitro and animal experimental studies suggests that beneficial effects of LIPUS on bone healing may include a positive impact on signal transduction, gene expression, blood flow, and tissue modeling and remodeling(khan and Laurencin 2008). Based on the clinical data, LIPUS reduces time to healing (approximately 40%) in non-operatively managed radius and tibial fractures by a mean of 32 days (154 v 122 days)(cook, Ryaby et al. 1997). Heckman and colleagues(heckman, Ryaby et al. 1994), and later Kristiansen and colleagues(kristiansen, Ryaby et al. 1997), studied the influence of LIPUS on the healing rate of acute tibial shaft and distal radius fractures, respectively. Both showed a significant reduction in time to union, and neither of the studies 35
5 reported any complications from the ultrasound. Cook and colleagues(cook, Ryaby et al. 1997) further evaluated the data from Heckman and showed a reduction in the number of delayed unions with the use of ultrasound bone stimulation despite smoking. One economic analysis estimated savings of $13,259 per fracture(heckman and Sarasohn-Kahn 1997). This economic analysis considered both direct and indirect costs; however, data for this model were based on a case series of 60 patients and an ultrasound registry, using radiographic healing as a surrogate for functional recovery. Limited studies currently exist regarding the efficacy of LIPUS in fracture healing in animals with experimental diabetes(gebauer, Lin et al. 2002). Specific studies on the effect of LIPUS on elective fusion in diabetics do not exist but one may extrapolate from the current literature studying LIPUS upon elective foot and ankle fusions. In a 12-month prospective study, Coughlin and colleagues(coughlin, Smith et al. 2008) evaluated the healing rate and clinical results of patients undergoing primary subtalar arthrodeses with adjuvant LIPUS. Fifteen consecutive patients participated in the study, obtaining routine radiographs, CT scans, and clinical outcomes. The clinical and radiographic data were compared to a similar cohort of patients previously reported on that had not received ultrasound bone stimulation. Results of the patients who received ultrasound bone stimulation showed a statistically significant faster healing rate on plain radiographs at 9 weeks (p = 0.034) and CT scan at 12 weeks (p = 0.017). A 100% fusion rate was noted. The American Orthopaedic Foot and Ankle Society (AOFAS) ankle and hindfoot score was also improved at 12 months postoperatively, a finding that was statistically significant (p = 0.026). Coughlin s study(coughlin, Smith et al. 2008) is unique in being the first paper to prospectively evaluate ultrasound bone stimulation in primary hindfoot arthrodesis patients. While these patient did not have DM (actually an exclusion criteria), the faster rate of healing demonstrates its potential role in the high risk arthrodesis patient. Electrical Bone Stimulation With respect to foot and ankle surgery in high-risk patients, two techniques of electrical bone stimulation have been well-described: pulsed electromagnetic field (PEMF) and direct current (DC). PEMF devices use pulses of exogenous electrical potentials in the form of an electromagnetic field applied locally to the area of interest (fracture and/or nonunion site) to accelerate osseous healing. PEMF devices are worn directly on the skin or a cast, and are therefore a noninvasive method of augmenting bone healing in the management of patients at high risk for delayed union or nonunion, including diabetics. Long periods of use, ranging from 3 to 10 hours a day depending on the system, are recommended, whereas application below the recommended minimal period of 3 hours per day has been shown to significantly reduce the efficacy electrical bone stimulation with respect to union(garland, Moses et al. 1991). Hence, patient noncompliance is a potential issue. DC devices are internally applied with a subcutaneously placed battery unit that houses the anode, and an attached titanium cathode wire electrode placed into the fracture/fusion site. While the electrical current can be delivered at maximal intensity for constant stimulation at the operative site, and patient compliance is rarely an issue, DC devices have their own disadvantages, namely local irritation or pain at the site of hardware implantation, and the potential need for a secondary procedure for hardware removal in case of infection (Figure 12). Several studies(donley and Ward 2002; Dhawan, Conti et al. 2004; Lau, Stamatis et al. 2007) have demonstrated the beneficial effect of electrostimulation in the treatment of primary hindfoot fusions, while only one prospective study(dhawan, Conti et al. 2004) has described the clinical application of PEMF in primary foot and ankle arthrodesis. Dhawan and colleagues(donley and Ward 2002) performed a clinical trial consisting of 64 patients (144 joints) undergoing elective triple or subtalar arthrodesis (primary and revision) randomized into two groups (with and without postoperative PEMF). The study excluded patients considered to be at high risk for impaired bone healing, specifically those with rheumatoid arthritis, diabetes or corticosteroid use. Blinded radiographic analysis was performed to assess fusion. The mean time to union for the PEMF group was 12.9 weeks for primary subtalar fusions (100% unions), 12.2 weeks for talonavicular fusions, and 13.1 weeks for calcaneocuboid fusions, while the corresponding fusions in non-pemf control group demonstrated an average time to union of 14.5 weeks, 17.6 weeks, and 17.7 weeks, respectively. While determining time-to-union by assessing standard radiographs is not a reliable method for quantifying this endpoint(coughlin, Smith et al. 2008) and no sham PEMF units for 36
6 controls were used, this randomized prospective study showed a statistically significant reduction in time required for union in both the talonavicular and calcaneocuboid fusion groups treated with PEMF, and a trend towards faster union in the subtalar arthrodesis group. Interestingly, patients who had PEMF treatment for multiple joint arthrodeses showed a tendency for the remaining joints to fuse quicker when one of the joints fused rapidly. Donley and colleagues(donley and Ward 2002) conducted a case series to assess the outcome of DC device implantation and subsequent electrical bone stimulation in 13 patients with primary hindfoot or ankle fusions (six tibio-talo-calcaneal, three ankle, two subtalar, and two tibiocalcaneal arthrodeses). All patients enrolled in this study demonstrated at least two risk factors for nonunion, including a history of nonunion, smoking, and osteonecrosis of the talus. Postoperative follow-up at one year showed successful fusion in 12 of 13 patients (92%). Clinically, postoperative pain and modified AOFAS scores at one-year showed significant improvement when compared to preoperative scores. Complications were superficial infections requiring local wound care in 4 patients, and 8 patients reported the subcutaneous battery pack to be bothersome, 4 of which underwent surgical removal. Although the results of these investigations(donley and Ward 2002; Dhawan, Conti et al. 2004; Lau, Stamatis et al. 2007) show a positive influence of electrical bone stimulation on the fusion rates in foot and ankle primary arthrodeses, and are therefore promising, insufficient evidence exist to support the routine use of PEMF or DC devices in primary arthrodesis. Additionally, the use of invasive DC devices with its concomitant risks over PEMF devices for primary arthrodesis is not supported by sufficient clinical data. Because foot and ankle arthrodesis procedures pose a high nonunion risk, considerable interest has been generated regarding the application of electrostimulation to revision arthrodeses. However, only one case series by Saltzman and colleagues(saltzman, Lightfoot et al. 2004) has described the effect of PEMF on revision arthrodesis. In this retrospective study, 19 patients who developed nonunion after primary foot and ankle arthrodeses were treated with PEMF, immobilization, and limited weight-bearing. Only 5 of the 19 patients went on to achieve union, while 9 of the remaining 14 underwent revision surgery yielding similar fusion rates (2 of 9). Patients risk factors included smoking (5 patients) and previous non unions (8 patients). The authors hypothesized that the lower rate of success of PEMF for revision arthrodesis of the foot and ankle, when compared to its application on long bones (de Haas, Watson et al. 1980; Heckman, Ingram et al. 1981; Bassett, Mitchell et al. 1982; Sharrard 1990; Holmes 1994), may be attributable to mechanical difficulties in orienting the coils around the foot and ankle. Contrary to Saltzman s results, Midis and Conti(Midis and Conti 2002) reported a case series of 10 consecutive patients with aseptic nonunions of the ankle requiring revision arthrodesis, supplemented with DC bone stimulation. Radiographic evidence showed that acceptable clinical alignment and solid fusion was achieved in all 10 patients at a mean of 12.8 weeks after revision surgery. Additionally, clinical examination through a modified AOFAS ankle/hindfoot scoring system showed 70% good to excellent results. In view of the limited number of clinical studies and their associated findings, which demonstrate inconsistent outcomes, it is difficult to justify the utility of electrical bone stimulation on foot and ankle revision arthrodeses. Furthermore, contrary to the previous indications, limited data exist to support the use of DC devices over PEMF devices for revision arthrodesis. Nonunion and delayed union occur frequently in certain high-risk foot and ankle fractures, such as tibial (shaft and pilon) and metaphyseal- diaphyseal fifth metatarsal fractures. In an effort to prevent these potential complications, some orthopaedic surgeons have used electrical bone stimulation upon fresh fractures. However, there is no peer-reviewed literature at this time that demonstrates the beneficial effect of the utility of electrical bone stimulation upon fresh fracture healing. Therefore, prospective, randomized controlled studies are required before routine clinical use can be considered in this scenario. BONE MARROW ASPIRATION The concept of osteogenic capacity of bone marrow aspiration is not novel (Burwell 1964; Burwell 1966; Beresford 1989) and has been exploited by several to reinforce the osteogenic properties of bone allograft by the augmentation of the graft with bone marrow(burwell 1985; Boehm and Muschler 1999) and its use in several tibia non union clinical series(connolly, Guse et al. 1989; Hernigou, Poignard et al. 2005). 37
7 Hernigou et al (Hernigou, Poignard et al. 2005)recently evaluated the number and concentration of progenitor cells in bone marrow concentrate for the treatment of tibia non-union, the callus volume after transplantation of concentrated bone marrow, and clinical union rate. First, aspiration contained an average of progenitors/cm3 before concentration and at average of progenitors/cm3 after concentration. The bone marrow that had been injected into non-union contained >1500 progenitors/cm3 and averaged total of 59, ,431 progenitors. Osseous union was obtained in 53 of 60 patients. The concentration( progenitor/cm3) and the total number (17, ) of progenitor injected into the non-union site of seven patients in whom non-union was not obtained were both significantly lower(p=0.0001and p<0.01, respectively) than those in patients who achieved union. The surgical technique of percutaneous autologous bone marrow grafting appears to be effective but its efficacy appears to be related to the number of progenitor in the graft and the number of progenitors available in bone marrow aspirated from the iliac crest graft appear to be less than optimal in absence of concentration. Al-Zube, L., E. A. Breitbart, et al. (2009). "Recombinant human platelet-derived growth factor BB (rhpdgf- BB) and beta-tricalcium phosphate/collagen matrix enhance fracture healing in a diabetic rat model." J Orthop Res 27(8): Alsousou, J., M. Thompson, et al. (2009). "The biology of platelet-rich plasma and its application in trauma and orthopaedic surgery: a review of the literature." J Bone Joint Surg Br 91(8): Alvarez, R. H., H. M. Kantarjian, et al. (2006). "Biology of platelet-derived growth factor and its involvement in disease." Mayo Clin Proc 81(9): Alvine, F. G. (2002). "The Agility ankle replacement: the good and the bad." Foot Ankle Clin 7(4): , vi. Axelrad, T. W. and T. A. Einhorn (2009). "Bone morphogenetic proteins in orthopaedic surgery." Cytokine Growth Factor Rev 20(5-6): Barrow, C. R. and G. C. Pomeroy (2005). "Enhancement of syndesmotic fusion rates in total ankle arthroplasty with the use of autologous platelet concentrate." Foot Ankle Int 26(6): Bassett, C. A., S. N. Mitchell, et al. (1982). "Treatment of therapeutically resistant non-unions with bone grafts and pulsing electromagnetic fields." J Bone Joint Surg Am 64(8): Beresford, J. (1989). "Osteogenic stem cells and the stromal system of bone and marrow." Clin Orthop Relat Res 200: Bibbo, C., C. M. Bono, et al. (2005). "Union rates using autologous platelet concentrate alone and with bone graft in high-risk foot and ankle surgery patients." J Surg Orthop Adv 14(1): Bibbo, C., Haskell, MD (2007). "Recombinant bone morphogenetic protein-2 (rhbmp-2) in high-risk foot and ankle surgery: surgical techniques and preliminary results of a prospective, intention-to-treat study." Techniques in Foot and Ankle Surgery 6(2): Bibbo, C., D. V. Patel, et al. (2009). "Recombinant bone morphogenetic protein-2 (rhbmp-2) in high-risk ankle and hindfoot fusions." Foot Ankle Int 30(7): Boehm, C. and G. Muschler (1999). "Rapid concentration of bone marrow derived osteoblastic progenitor cells(cfu-os) in allograft bone powder." J Bone Miner Res 14(Suppl D): S474. Bostrom, M. P. and P. Asnis (1998). "Transforming growth factor beta in fracture repair." Clin Orthop(355 Suppl): S Bostrom, M. P., J. M. Lane, et al. (1995). "Immunolocalization and expression of bone morphogenetic proteins 2 and 4 in fracture healing." J Orthop Res 13(3): Burwell, R. (1964). "Studies in the transplantation of bone. VII. The fresh composite homograft-autograft of cancellous bone; an analysis of factors leading to osteogenesis in marrow transplants and in marrow-containing bone grafts." J Bone Joint Surg Br 46: Burwell, R. (1966). "Studies in the transplantation of bone.8. Treated composite homograft-autografts of cancellous bone: an analysis of inductive mechanisms in bone transplantation." J Bone Joint Surg Br 48: Burwell, R. (1985). "The function of bone marrow in the incorporation of a bone graft." Clin Orthop Relat Res 200:
8 Busse, J. W., E. Morton, et al. (2008). "Current management of tibial shaft fractures: a survey of 450 Canadian orthopedic trauma surgeons." Acta Orthop 79(5): Cho, T. J., L. C. Gerstenfeld, et al. (2002). "Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing." J Bone Miner Res 17(3): Coetzee, J. C., G. C. Pomeroy, et al. (2005). "The use of autologous concentrated growth factors to promote syndesmosis fusion in the Agility total ankle replacement. A preliminary study." Foot Ankle Int 26(10): Connolly, J. F., R. Guse, et al. (1989). "Autologous marrow injection as a substitute for operative grafting of tibial nonunions." Clin Orthop Relat Res 266: Cook, S. D., J. P. Ryaby, et al. (1997). "Acceleration of tibia and distal radius fracture healing in patients who smoke." Clin Orthop Relat Res(337): Coughlin, M. J., B. W. Smith, et al. (2008). "The evaluation of the healing rate of subtalar arthrodeses, part 2: the effect of low-intensity ultrasound stimulation." Foot Ankle Int 29(10): Dallari, D., L. Savarino, et al. (2007). "Enhanced tibial osteotomy healing with use of bone grafts supplemented with platelet gel or platelet gel and bone marrow stromal cells." J Bone Joint Surg Am 89(11): de Haas, W. G., J. Watson, et al. (1980). "Non-invasive treatment of ununited fractures of the tibia using electrical stimulation." J Bone Joint Surg Br 62-B(4): DelRossi, A. J., A. C. Cernaianu, et al. (1990). "Platelet-rich plasma reduces postoperative blood loss after cardiopulmonary bypass." J Thorac Cardiovasc Surg 100(2): Dhawan, S. K., S. F. Conti, et al. (2004). "The effect of pulsed electromagnetic fields on hindfoot arthrodesis: a prospective study." J Foot Ankle Surg 43(2): Dohan Ehrenfest, D. M., L. Rasmusson, et al. (2009). "Classification of platelet concentrates: from pure platelet-rich plasma (P-PRP) to leucocyte- and platelet-rich fibrin (L-PRF)." Trends Biotechnol 27(3): Donley, B. G. and D. M. Ward (2002). "Implantable electrical stimulation in high-risk hindfoot fusions." Foot Ankle Int 23(1): Eppley, B. L., W. S. Pietrzak, et al. (2006). "Platelet-rich plasma: a review of biology and applications in plastic surgery." Plast Reconstr Surg 118(6): 147e-159e. Foster, T. E., B. L. Puskas, et al. (2009). "Platelet-rich plasma: from basic science to clinical applications." Am J Sports Med 37(11): Gandhi, A., C. Bibbo, et al. (2005). "The role of platelet-rich plasma in foot and ankle surgery." Foot Ankle Clin 10(4): , viii. Garland, D. E., B. Moses, et al. (1991). "Long-term follow-up of fracture nonunions treated with PEMFs." Contemp Orthop 22(3): Gebauer, G. P., S. S. Lin, et al. (2002). "Low-intensity pulsed ultrasound increases the fracture callus strength in diabetic BB Wistar rats but does not affect cellular proliferation." J Orthop Res 20(3): Hall, M. P., P. A. Band, et al. (2009). "Platelet-rich plasma: current concepts and application in sports medicine." J Am Acad Orthop Surg 17(10): Heckman, J. D., A. J. Ingram, et al. (1981). "Nonunion treatment with pulsed electromagnetic fields." Clin Orthop Relat Res(161): Heckman, J. D., J. P. Ryaby, et al. (1994). "Acceleration of tibial fracture-healing by non-invasive, lowintensity pulsed ultrasound." J Bone Joint Surg Am 76(1): Heckman, J. D. and J. Sarasohn-Kahn (1997). "The economics of treating tibia fractures. The cost of delayed unions." Bull Hosp Jt Dis 56(1): Hernigou, P., A. Poignard, et al. (2005). "Percutaneous autologous bone-marrow grafting for nonunions." J Bone Joint Surg Am 87A: Hollinger, J. O., C. E. Hart, et al. (2008). "Recombinant human platelet-derived growth factor: biology and clinical applications." J Bone Joint Surg Am 90 Suppl 1:
9 Hollinger, J. O., A. O. Onikepe, et al. (2008). "Accelerated fracture healing in the geriatric, osteoporotic rat with recombinant human platelet-derived growth factor-bb and an injectable beta-tricalcium phosphate/collagen matrix." J Orthop Res 26(1): Holmes, G. B., Jr. (1994). "Treatment of delayed unions and nonunions of the proximal fifth metatarsal with pulsed electromagnetic fields." Foot Ankle Int 15(10): Ishidou, Y., I. Kitajima, et al. (1995). "Enhanced expression of type I receptors for bone morphogenetic proteins during bone formation." J Bone Miner Res 10(11): Khan, Y. and C. T. Laurencin (2008). "Fracture repair with ultrasound: clinical and cell-based evaluation." J Bone Joint Surg Am 90 Suppl 1: Kitoh, H., T. Kitakoji, et al. (2007). "Distraction osteogenesis of the lower extremity in patients with achondroplasia/hypochondroplasia treated with transplantation of culture-expanded bone marrow cells and platelet-rich plasma." J Pediatr Orthop 27(6): Kitoh, H., T. Kitakoji, et al. (2007). "Transplantation of culture expanded bone marrow cells and platelet rich plasma in distraction osteogenesis of the long bones." Bone 40(2): Kristiansen, T. K., J. P. Ryaby, et al. (1997). "Accelerated healing of distal radial fractures with the use of specific, low-intensity ultrasound. A multicenter, prospective, randomized, double-blind, placebocontrolled study." J Bone Joint Surg Am 79(7): Lau, J. T., E. D. Stamatis, et al. (2007). "Implantable direct-current bone stimulators in high-risk and revision foot and ankle surgery: a retrospective analysis with outcome assessment." Am J Orthop 36(7): Lieberman, J. R., A. Daluiski, et al. (2002). "The role of growth factors in the repair of bone. Biology and clinical applications." J Bone Joint Surg Am 84-A(6): Lowery, G. L., S. Kulkarni, et al. (1999). "Use of autologous growth factors in lumbar spinal fusion." Bone 25(2 Suppl): 47S-50S. Marx, R. E., E. R. Carlson, et al. (1998). "Platelet-rich plasma: Growth factor enhancement for bone grafts." Oral Surg Oral Med Oral Pathol Oral Radiol Endod 85(6): Midis, N. and S. F. Conti (2002). "Revision ankle arthrodesis." Foot Ankle Int 23(3): Mishra, A., J. Woodall, Jr., et al. (2009). "Treatment of tendon and muscle using platelet-rich plasma." Clin Sports Med 28(1): Nakase, T., S. Nomura, et al. (1994). "Transient and localized expression of bone morphogenetic protein 4 messenger RNA during fracture healing." J Bone Miner Res 9(5): Onishi, T., Y. Ishidou, et al. (1998). "Distinct and overlapping patterns of localization of bone morphogenetic protein (BMP) family members and a BMP type II receptor during fracture healing in rats." Bone 22(6): Pinzur, M. S. (2009). "Use of platelet-rich concentrate and bone marrow aspirate in high-risk patients with Charcot arthropathy of the foot." Foot Ankle Int 30(2): Pyevich, M. T., C. L. Saltzman, et al. (1998). "Total ankle arthroplasty: a unique design. Two to twelve-year follow-up." J Bone Joint Surg Am 80(10): Reddi, A. H. (1994). "Bone and cartilage differentiation." Curr Opin Genet Dev 4(5): Rubin, C., M. Bolander, et al. (2001). "The use of low-intensity ultrasound to accelerate the healing of fractures." J Bone Joint Surg Am 83-A(2): Saltzman, C., A. Lightfoot, et al. (2004). "PEMF as treatment for delayed healing of foot and ankle arthrodesis." Foot Ankle Int 25(11): Saltzman, C. L. and F. G. Alvine (2002). "The Agility total ankle replacement." Instr Course Lect 51: Sharrard, W. J. (1990). "A double-blind trial of pulsed electromagnetic fields for delayed union of tibial fractures." J Bone Joint Surg Br 72(3): Shi, Y. and J. Massague (2003). "Mechanisms of TGF-beta signaling from cell membrane to the nucleus." Cell 113(6): Tayapongsak, P., D. A. O'Brien, et al. (1994). "Autologous fibrin adhesive in mandibular reconstruction with particulate cancellous bone and marrow." J Oral Maxillofac Surg 52(2): ; discussion 166. Wozney, J., Rosen V (1993). Bone morphogenic proteins and their expression. M. Noda. San Diego, Academic Press:
10 Yoshimura, Y., S. Nomura, et al. (2001). "Colocalization of noggin and bone morphogenetic protein-4 during fracture healing." J Bone Miner Res 16(5):
AOFAS Resident Review Course September 28, Sheldon S. Lin, MD Associate Professor North Jersey Orthopaedic Institute University Hospital
Course September 28, 2013 Sheldon S. Lin, MD Associate Professor North Jersey Orthopaedic Institute University Hospital Disclosures Research support from Biomimetic of Wright, Tissuegene Lab of UMDNJ has
More informationOrthopedic & Sports Medicine, Bay Care Clinic, 501 N. 10th Street, Manitowoc, WI Procedure. Subtalar arthrodesis
OSTEOAMP Allogeneic Morphogenetic Proteins Subtalar Nonunions OSTEOAMP Case Report SUBTALAR NONUNIONS Dr. Jason George DeVries and Dr. Brandon M. Scharer Orthopedic & Sports Medicine, Bay Care Clinic,
More informationrhpdgf-bb/β-tcp TECHNOLOGY OVERVIEW AUGMENT Bone Graft THE FIRST AND ONLY PROVEN ALTERNATIVE TO AUTOGRAFT IN ANKLE AND HINDFOOT ARTHRODESIS
rhpdgf-bb/β-tcp TECHNOLOGY OVERVIEW AUGMENT Bone Graft THE FIRST AND ONLY PROVEN ALTERNATIVE TO AUTOGRAFT IN ANKLE AND HINDFOOT ARTHRODESIS AUGMENT Bone Graft T HE F I R S T A ND O N LY PROV EN A LT ERN
More informationWHEN TO ADD BONE STIMULATION
WHEN TO ADD BONE STIMULATION John Ketz, MD CSFS 2017 Bone Healing Fracture Hematoma (Immediate) Inflammatory Phase (Days) Reparative Phase (Weeks) Remodeling Phase (Months) 1/30/2017 2 Bone Healing Multiple
More informationORTHOPEDICS BONE Recalcitrant nonunions In total hip replacement total knee surgery increased callus volume
ORTHOPEDICS Orthopedics has to do with a variety of tissue: bone, cartilage, tendon, ligament, muscle. In this regard orthopedic and sports medicine share the same tissue targets. Orthopedics is mostly
More informationAUGMENT. Bone Graft. Tibiotalar Fusion. rhpdgf-bb/β-tcp THE FIRST AND ONLY PROVEN ALTERNATIVE TO AUTOGRAFT IN ANKLE AND HINDFOOT ARTHRODESIS
rhpdgf-bb/β-tcp AUGMENT Bone Graft THE FIRST AND ONLY PROVEN ALTERNATIVE TO AUTOGRAFT IN ANKLE AND HINDFOOT ARTHRODESIS CASE REPORT Tibiotalar Fusion as presented by Mark Glazebrook, MD Assoc Professor
More informationAnkle and subtalar arthrodesis
OSTEOAMP Allogeneic Morphogenetic Proteins Ankle Nonunions OSTEOAMP Case Report ANKLE NONUNIONS Dr. Jason George DeVries Orthopedic & Sports Medicine, Bay Care Clinic, 501 N. 10th Street, Manitowoc, WI
More information61 (17 direct current, 22 pulsed electromagnetic field, 22 control) 116 Osteonecrosis radiographic progression and Harris hip score
Page 1 Appendix TABLE E-1 Summary of Included Clinical Studies* Type of Stimulation and Study Level of Evidence Indication Tested No. of Patients Outcome Measure Result Direct current Andersen 44 I Spinal
More informationAnabolic Therapy With Teriparatide Indications Beyond Osteoporosis
Anabolic Therapy With Teriparatide Indications Beyond Osteoporosis Andreas Panagopoulos MD, PhD Upper Limb & Sports Medicine Orthopaedic Surgeon Assistant Professor, University of Patras Outline Teriparatide
More informationEnhancement of fracture healing-current trends
Enhancement of fracture healing-current trends DR. CHETAN PRADHAN MS, F.ASIF (Swiss) CONSULTANT ORTHOPAEDIC SURGEON SANCHETI HOSPITAL, PUNE. Iliac crest : the gold standard Osteogenicity : ability to form
More informationIsolated Subtalar or Talonavicular Fusion Has Failed. Now What?
Isolated Subtalar or Talonavicular Fusion Has Failed. Now What? Anish R. Kadakia MD Associate Professor Northwestern University: Feinberg School of Medicine Northwestern Memorial Hospital Department of
More informationDisclosure. Endochondral Healing 4/28/2016. Fracture Healing Stimulation Where s the Evidence?
Fracture Healing Stimulation Where s the Evidence? Thomas J Moore MD Atlanta Trauma Symposium April 23, 2016 Disclosure Member: AAOS Committee on Biologics Reviewer: Clinical Orthopaedics Related Research
More informationThe Latest Breakthrough in TTC Fusion Technology
The Latest Breakthrough in TTC Fusion Technology Treatment of Hindfoot Non-Union with DynaNail TTC Fusion System A CASE REPORT Dr. L. Daniel Latt, MD, PhD Background The DynaNail TTC Fusion System is intended
More informationProtocol. Ultrasound Accelerated Fracture Healing Device
Protocol Ultrasound Accelerated Fracture Healing Device (10105) Medical Benefit Effective Date: 04/01/14 Next Review Date: 01/15 Preauthorization Yes Review Dates: 09/07, 09/08, 09/09, 05/10, 05/11, 01/12,
More informationClinical Review Criteria
Clinical Review Criteria Autologous Platelet Derived Wound Healing Factors for Treatment of: Non Healing Cutaneous Wounds (Procuren) Non-Healing Fractures and the Associated GEM 21STM Device Platelet Rich
More informationDescription. Section: Surgery Effective Date: April 15, 2015 Subsection: Surgery Original Policy Date: June 7, 2012 Subject: Page: 1 of 11
Subject: Electrical Bone Growth Stimulation of the Last Review Status/Date: March 2015 Page: 1 of 11 Electrical Bone Growth Stimulation of the Description In the appendicular skeleton, electrical stimulation
More informationTobacco and Bone Health
Tobacco and Bone Health Prof. Dr. Alok Chandra Agrawal MS Orthopaedics, DNB Orthopaedics, PhD Orthopaedics MAMS All India Institute of Medical Sciences Raipur CG Cigarette smoking is commonly identified
More informationPRP Basic Science. Platelets. Definition of PRP 10/4/2011. Questions that this talk aims to answer
PRP Basic Science Peter J. Moley, MD Hospital for Special Surgery October 5, 2011 Questions that this talk aims to answer 1. What is PRP? 2. What blood components are NOT in PRP? 3. What are the active
More informationElectrical Bone Growth Stimulation of the Appendicular Skeleton
7.01.07 Electrical Bone Growth Stimulation of the Appendicular Skeleton Section 7.0 Surgery Subsection Effective Date February 15, 2015 Original Policy Date June 11, 2014 Next Review Date December 2015
More informationThe Effect of Bone Marrow Aspirate Concentrate (BMAC) and Platelet-Rich Plasma (PRP) during Distraction Osteogenesis of the Tibia
The Effect of Bone Marrow Aspirate Concentrate (BMAC) and Platelet-Rich Plasma (PRP) during Distraction Osteogenesis of the Tibia Dong Hoon Lee, MD, Ph.D, Keun Jung Ryu MD Limb Lengthening and Deformity
More informationAbstract. Firas T. Ismaeel, Dept. of Surgery, College of Medicine, Tikrit University
Bone marrow injection in patients with delayed union and non-union of long Firas T. Ismaeel, Dept. of Surgery, College of Medicine, Tikrit University Abstract In the process of bone formation and healing
More informationElectrical Bone Growth Stimulation of the Appendicular Skeleton
Electrical Bone Growth Stimulation of the Appendicular Skeleton Policy Number: 7.01.07 Last Review: 8/2014 Origination: 8/2002 Next Review: 8/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationAUGMENT. Bone Graft. rhpdgf-bb/β-tcp SURGICAL TECHNIQUE
rhpdgf-bb/β-tcp SURGICAL TECHNIQUE AUGMENT Bone Graft T HE F I R S T A ND O N LY PROV EN A LT ERN AT I V E TO AU TO GR A F T IN A NK LE A ND HINDFOOT A RT HRODESIS The Time Has Come to Augment Your Fusion.
More informationPRP Usage in Today's Implantology
Volume 1, December 2004 www.implant.co.il PRP Usage in Today's Implantology by Dr. R. Shapira Introduction: Treating patients suffering from hematological disorders or using anticoagulant medications always
More informationProtocol. Ultrasound Accelerated Fracture Healing Device
Protocol Ultrasound Accelerated Fracture Healing Device (10105) Medical Benefit Effective Date: 04/01/14 Next Review Date: 01/17 Preauthorization Yes Review Dates: 09/07, 09/08, 09/09, 05/10, 05/11, 01/12,
More informationSubject: Ultrasound Osteogenesis Stimulators, Non Invasive
Date Printed: March 7, 2016: 10:37 AM Private Property of Blue Cross and Blue Shield of Florida. This medical policy (medical coverage guideline) is Copyright 2016, Blue Cross and Blue Shield of Florida
More informationCare of the Foot and Ankle
Care of the Foot and Ankle DaVinci Christopher W. DiGiovanni, MD Chief, Division of Foot and Ankle Professor & Program Director, Dept. Orthopaedic Surgery The Warren Alpert School of Medicine at Brown
More informationMechanism of Action. Activating bone healing at every stage
Mechanism of Action Activating bone healing at every stage Ultrasound Bone Healing System Mechanism of Action The Bone Healing System is a unique fracture healing device that uses low intensity pulsed
More informationAn Owner's Guide to Natural Healing. Autologous Conditioned Plasma (ACP)
An Owner's Guide to Natural Healing Autologous Conditioned Plasma (ACP) Healing after an injury involves a well-orchestrated and complex series of events where proteins in the blood have primary roles,
More informationBONE AUGMENTATION AND GRAFTING
1 A Computer-Guided Bone Block Harvesting Procedure: A Proof-of-Principle Case Report and Technical Notes Effectiveness of Lateral Bone Augmentation on the Alveolar Crest Dimension: A Systematic Review
More informationCorporate Medical Policy
Corporate Medical Policy Ultrasound Accelerated Fracture Healing Device File Name: Origination: Last CAP Review: Next CAP Review: Last Review: ultrasound_accelerated_fracture_healing_device 12/1994 2/2017
More informationClinical Policy Title: Bone growth stimulators for non-healing fractures
Clinical Policy Title: Bone growth stimulators for non-healing fractures Clinical Policy Number: 14.02.03 Effective Date: January 1, 2015 Initial Review Date: July 16, 2014 Most Recent Review Date: March
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Effective Date: July 15, 2017 Related Policies: 1.01.05 Ultrasound Accelerated Fracture Healing Device 7.01.85 Electrical Stimulation of the Spine as an Adjunct to Spinal Fusion
More informationBone Grafting and Bone Graft Substitutes. Original Author: James Krieg, MD Revision Author: David Hak, MD Last Revision May 2010
Bone Grafting and Bone Graft Substitutes Original Author: James Krieg, MD Revision Author: David Hak, MD Last Revision May 2010 Bone Graft Function Structural support of articular fracture Tibial plateau
More informationMechanism of Action. Activating bone healing at every stage
Mechanism of Action Activating bone healing at every stage EXOGEN Ultrasound Bone Healing System The EXOGEN Ultrasound Bone Healing System is an FDA-approved bone healing device that uses low intensity
More informationMechanism of Action. Activating bone healing at every stage
Mechanism of Action Activating bone healing at every stage EXOGEN Ultrasound Bone Healing System The EXOGEN Bone Healing System is a unique fracture healing device that uses low intensity pulsed ultrasound
More informationMesenchymal Stem Cell Therapy for Orthopedic Indications. Original Policy Date
MP 2.01.59 Mesenchymal Stem Cell Therapy for Orthopedic Indications Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Local policy created/12:2013 Return
More informationCharcot Foot: Potential Pearls from Parkland
Charcot Foot: Potential Pearls from Parkland Javier La Fontaine, D.P.M., M.S. Professor Department of Plastic Surgery UT Southwestern Medical Center Dallas, Texas Objectives To share the experience from
More informationMost cells in the human body have an assigned purpose. They are liver cells, fat cells, bone cells,
What is a Stem Cell? Most cells in the human body have an assigned purpose. They are liver cells, fat cells, bone cells, and so on. These cells can replicate more of their own kind of cell, but they cannot
More informationCalcium Phosphate Cement
Calcium Phosphate Cement Fast-Setting Bone Graft and AutoGraft Extender. * Ossilix is a high performance next generation calcium phosphate cement indicated for filling bony defects in cancellous bone.
More informationElectrical Bone Growth Stimulators (Osteogenic Stimulation)
Medical Policy Manual Durable Medical Equipment, Policy No. 83.11 Electrical Bone Growth Stimulators (Osteogenic Stimulation) Next Review: July 2018 Last Review: September 2017 Effective: October 1, 2017
More informationRetrospective Study of Surgical Outcomes for Combined Ankle and Subtalar Joint Arthrodesis, Cavovarus Deformity Correction and Ankle Fractures
FOOT/ ANKLE RETROSPECTIVE STUDYIC S Retrospective Study of Surgical Outcomes for Combined Ankle and Subtalar Joint Arthrodesis, Cavovarus Deformity Correction and Ankle Fractures Adult & Pediatric Deformity
More informationCorporate Medical Policy
Corporate Medical Policy Electrical Bone Growth Stimulation File Name: Origination: Last CAP Review: Next CAP Review: Last Review: electrical_bone_growth_stimulation 4/1981 6/2017 6/2018 6/2017 Description
More informationOriginal Policy Date 12/1/9512:2013
MP 1.01.03 Ultrasound Accelerated Fracture Healing Device Medical Policy Section Durable Medical Equipment Issue 12:2013 Original Policy Date 12/1/9512:2013 Last Review Status/Date 12:2013 Return to Medical
More informationFoot, Ankle, Knee & Hip Surgery Update. What s s New. Platelet Rich Plasma (PRP) Platelet Rich Plasma Total Ankle Replacement.
Foot, Ankle, Knee & Hip Surgery Update Geoffrey S. Landis D.O. April 29, 2010 Southwestern Conference on Medicine What s s New Platelet Rich Plasma Total Platelet Rich Plasma (PRP) Why- Need or Desire
More informationMULTIPLE APPLICATIONS OF THE MINIRAIL
C H A P T E R 2 1 MULTIPLE APPLICATIONS OF THE MINIRAIL Thomas J. Merrill, DPM James M. Losito, DPM Mario Cala, DPM Victor Herrera, DPM Alan E. Sotelo, DPM INTRODUCTION The unilateral MiniRail External
More informationSubject: Non-Invasive Electrical Bone Growth Stimulators (EBGS)
09-E0000-22 Original Effective Date: 06/15/00 Reviewed: 04/28/16 Revised: 05/15/16 Subject: Non-Invasive Electrical Bone Growth Stimulators (EBGS) THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION,
More informationPOLICIES AND PROCEDURE MANUAL
POLICIES AND PROCEDURE MANUAL Policy: MP029 Section: Medical Benefit Policy Subject: Bone Growth Stimulator I. Policy: Bone Growth Stimulator II. Purpose/Objective: To provide a policy of coverage regarding
More informationchronos Bone Void Filler. Beta-Tricalcium Phosphate ( β-tcp) bone graft substitute.
chronos Bone Void Filler. Beta-Tricalcium Phosphate ( β-tcp) bone graft substitute. Osteoconductive Resorbable Synthetic chronos Bone Void Filler chronos granules and preforms are synthetic, porous, osteoconductive,
More informationA gift you do not want. Motion Avascularity Gap Infection. Prognostic Issues. BMA & BMP: Alternative to Autologous BG? 11/21/2016.
BMA & BMP: Alternative to Autologous BG? Frank A. Liporace, MD Associate Professor Dept. of Orthopaedics Director Orthopaedic Trauma Research New York University / Hospital for Joint Diseases, NY, NY Chairman
More informationRole of Percutaneous Autologous Bone Marrow Grafting In Non-union Tibia
ORIGINAL ARTICLE Role of Percutaneous Autologous Bone Marrow Grafting In Non-union Tibia Faaiz Ali Shah, Zahir Khan, Zulfiqar Ali Durrani, Ismatullah, Kifayatullah, Haziqdad Khan ABSTRACT Objective Study
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Electrical Bone Growth Stimulation Page 1 of 42 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Electrical Bone Growth Stimulation of the Appendicular Skeleton
More informationSredišnja medicinska knjižnica.
Središnja medicinska knjižnica Pećina, M., Vukičević, S. (2007) Biological aspects of bone, cartilage and tendon regeneration. International Orthopaedics, 31 (6). pp. 719-720. The original publication
More informationLawrence A. DiDomenico, DPM, FACFAS
Lawrence A. DiDomenico, DPM, FACFAS Adjunct Professor, Kent State University College of Podiatric Medicine, Cleveland, Ohio USA Director, Reconstructive Rearfoot & Ankle Surgical Fellowship, Ankle and
More informationAnkle Fractures: The Bad and the Ugly
Ankle Fractures: The Bad and the Ugly Florida Podiatric Medical Association Science & Management Symposium January 12, 2018 Alan A. MacGill, DPM, FACFAS, AO Fellow Director, Foot & Ankle Surgery Residency
More informationThe Use of Bone Stimulators With Athletes. James Sullivan DPM, ATC EATA Symposium 2006 Philadelphia, Pennsylvania
The Use of Bone Stimulators With Athletes James Sullivan DPM, ATC EATA Symposium 2006 Philadelphia, Pennsylvania Bone Anatomical Structure Physiological Organ Bone Anatomical Structure Provides rigid framework
More informationOrthobiologics In Orthopaedic Trauma
Orthobiologics In Orthopaedic Trauma Aaron Nauth, MD, MSc Chair in Fracture Care Research St. Michael s Hospital, University of Toronto Created August 2017 Previous Versions J. Tracy Watson (2007, 2010)
More informationOriginal Policy Date
MP 8.01.30 Orthopedic Applications of Stem Cell Therapy Medical Policy Section Therapy Issue 12/2013 Original Policy Date 12/2013 Last Review Status/Date Reviewed with literature search/12/2013 Return
More informationTechnique Guide. 6.5 mm Midfoot Fusion Bolt. For intramedullary fixation of the medial column of the foot.
Technique Guide 6.5 mm Midfoot Fusion Bolt. For intramedullary fixation of the medial column of the foot. Table of Contents Introduction 6.5 mm Midfoot Fusion Bolt 2 AO Principles 4 Indications 5 Surgical
More informationUltrasound Accelerated Fracture Healing Device. Description
Subsection: Equipment Original Policy March 9, 2012 Subject: Ultrasound Accelerated Fracture Healing Device Date: Page: 1 of 13 Last Review Status/Date: December 2016 Ultrasound Accelerated Fracture Healing
More informationLow Intensity Ultrasound Accelerated Fracture Healing Device
Page 1 of 14 Medical Policies - DME Low Intensity Ultrasound Accelerated Fracture Healing Device Print Number: DME101.030 Effective Date: 01-01-2015 Coverage: Low-intensity ultrasound treatment may be
More informationCONFORM FlEX. Demineralized cancellous bone
CONFORM FlEX Demineralized cancellous bone TABlE OF CONTENTS introduction 2 FEATURES AND BENEFiTS 4 PROCESSiNg AND PACKAgiNg information 5 MUSCUlOSKElETAl TRANSPlANT FOUNDATiON (MTF) 6 ORDERiNg information
More informationResearch Article Evaluation of Amniotic-Derived Membrane Biomaterial as an Adjunct for Repair of Critical Sized Bone Defects
Advances in Orthopedic Surgery, Article ID 572586, 4 pages http://dx.doi.org/10.1155/2014/572586 Research Article Evaluation of Amniotic-Derived Membrane Biomaterial as an Adjunct for Repair of Critical
More informationBiologics in ACL: What s the Data?
Biologics in ACL: What s the Data? Jo A. Hannafin, M.D., Ph.D. Professor of Orthopaedic Surgery, Weill Cornell Medical College Attending Orthopaedic Surgeon and Senior Scientist Sports Medicine and Shoulder
More informationConversion of Pantalar fusion to total ankle replacement: A case Review. Key words: Pantalar fusion, non-union and total ankle replacement
The Northern Ohio Foot and Ankle Journal Official Publication of the NOFA Foundation Conversion of Pantalar fusion to total ankle replacement: A case Review Author: Bryan Williams DPM 1 and Jonathan Sharpe
More informationOrthopedic Applications of Platelet- Rich Plasma
Orthopedic Applications of Platelet- Rich Plasma Policy Number: 2.01.98 Last Review: 5/2018 Origination: 5/2016 Next Review: 5/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide
More informationDiabetics. Referred for management of complex pilon fracture? 5/10/2017. Pilon Fractures: Exfix as definitive treatment (DM?)
Pilon Fractures: Exfix as definitive treatment (DM?) Nirmal C Tejwani, MD Professor, NYU Langone Orthopedics Chief of Trauma, Bellevue Hospital, New York, NY 29 th Annual Orthopaedic Trauma Meeting May
More informationProspective Randomized Controlled Trial of Hindfoot and Ankle Fusions Treated With rhpdgf-bb in Combination With a β-tcp-collagen Matrix
576370FAIXXX10.1177/1071100715576370Foot & Ankle InternationalDaniels et al research-article2015 Article Prospective Randomized Controlled Trial of Hindfoot and Ankle Fusions Treated With rhpdgf-bb in
More informationRadiology Case Reports. Bone Graft Extruded From an Intramedullary Nail Tract in the Tibia. Penelope J. Galbraith, M.D., and Felix S. Chew, M.D.
Radiology Case Reports Volume 2, Issue 4, 2007 Bone Graft Extruded From an Intramedullary Nail Tract in the Tibia Penelope J. Galbraith, M.D., and Felix S. Chew, M.D. A 33-year-old man presented for follow
More information.org. Tibia (Shinbone) Shaft Fractures. Anatomy. Types of Tibial Shaft Fractures
Tibia (Shinbone) Shaft Fractures Page ( 1 ) The tibia, or shinbone, is the most common fractured long bone in your body. The long bones include the femur, humerus, tibia, and fibula. A tibial shaft fracture
More informationSinus Augmentation Studies Methods and Definition
FDA approved indications for Infuse Bone Graft in the Maxillofacial Skeleton Alveolar Ridge Augmentation (Buccal Wall Defects) in the Maxilla Maxillary Sinus Floor augmentation Sinus Augmentation Studies
More informationBone marrow injection in patients with delayed union and non-union of long bone fractures. Done by Dr.Firas T. Ismaeel
Bone marrow injection in patients with delayed union and non-union of long bone fractures Done by Dr.Firas T. Ismaeel Abstract Background: In the process of bone formation and healing of fractures, the
More informationThe Impact of Low-Intensity Pulsed Ultrasound (LIPUS) on Risk Factors for Fracture Nonunion
ORS would like to highlight the following article supported by funding from Bioventus LLC, Durham, NC as our thank you for being a Champion Corporate Supporter. To learn more about opportunities to support
More informationPopulations Interventions Comparators Outcomes Individuals: With fracture nonunion
Protocol Electrical Bone Growth Stimulation of the Appendicular Skeleton (70107) Medical Benefit Effective Date: 04/01/14 Next Review Date: 01/19 Preauthorization Yes Review Dates: 09/07, 09/08, 09/09,
More informationGeisinger Health Plan, Geisinger Indemnity Insurance Company and Geisinger Quality Options are
Bone Growth Stimulator Policy # : MP029 Last Review Date : 2015-10-23 Status : Active Cross References : Reviewed Geisinger Health Plan, Geisinger Indemnity Insurance Company and Geisinger Quality Options
More informationChoice of spacer material for HTO! P. Landreau, MD Chief of Surgery Aspetar, Orthopaedic and Sports Medicine Hospital Doha, Qatar
Choice of spacer material for HTO! P. Landreau, MD Chief of Surgery Aspetar, Orthopaedic and Sports Medicine Hospital Doha, Qatar High Tibial Osteotomy: HTO! Valgisation HTO Intended to transfer the mechanical
More informationDevelopments in bone grafting in veterinary orthopaedics part one
Vet Times The website for the veterinary profession https://www.vettimes.co.uk Developments in bone grafting in veterinary orthopaedics part one Author : John Innes, Peter Myint Categories : Vets Date
More informationInion BioRestore. Bone Graft Substitute. Product Overview
Inion BioRestore Bone Graft Substitute Product Overview Inion BioRestore Introduction Inion BioRestore is a synthetic bone graft substitute, which remodels into bone and is easy to use. Inion BioRestore
More informationJeannie Huh, MD Christopher Gross, MD Alex Lampley, MD Samuel B. Adams, MD James K. DeOrio, MD James A. Nunley II, MD Mark E.
Jeannie Huh, MD Christopher Gross, MD Alex Lampley, MD Samuel B. Adams, MD James K. DeOrio, MD James A. Nunley II, MD Mark E. Easley, MD Duke University Medical Center Durham, NC Disclosures Predictors
More informationElectrical Bone Growth Stimulation of the Appendicular Skeleton
Electrical Bone Growth Stimulation of the Appendicular Skeleton Policy Number: 7.01.07 Last Review: 8/2017 Origination: 8/2002 Next Review: 8/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationTREATMENT OF CARTILAGE LESIONS
TREATMENT OF CARTILAGE LESIONS Angelo J. Colosimo, MD -Head Orthopaedic Surgeon University of Cincinnati Athletics -Director of Sports Medicine University of Cincinnati Medical Center -Associate Professor
More information6.5 mm midfoot fusion bolt
6.5 mm midfoot fusion bolt For intramedullary fixation of the medial column of the foot SurgIcal technique Table of Contents Introduction 6.5 mm Midfoot Fusion Bolt 2 AO Principles 4 Indications 5 Surgical
More informationHorizon BCBSNJ Uniform Medical Policy Manual. Treatment. Section:
Horizon BCBSNJ Uniform Medical Policy Manual Section: Treatment Policy Number: 008 Effective Date: 08/12/2014 Original Policy Date: 10/05/1994 Last Review Date: 03/10/2015 Date Published to Web: 11/23/2011
More informationCASE REPORT. Antegrade tibia lengthening with the PRECICE Limb Lengthening technology
CASE REPORT Antegrade tibia lengthening with the PRECICE Limb Lengthening technology Austin T. Fragomen, M.D. Hospital for Special Surgery New York, NY 1 1 PR O D U CTS CONDITION Nonunion of an attempted
More informationOSTEOCHONDRAL ALLOGRAFT RECONSTRUCTION FOR MASSIVE BONE DEFECT
OSTEOCHONDRAL ALLOGRAFT RECONSTRUCTION FOR MASSIVE BONE DEFECT Angelo J. Colosimo, MD -Head Orthopaedic Surgeon University of Cincinnati Athletics -Director of Sports Medicine University of Cincinnati
More informationIncreased pressures at
Surgical Off-loading of Plantar Hallux Ulcerations These approaches can be used to treat DFUs. By Adam R. Johnson, DPM Increased pressures at the plantar aspect of the hallux leading to chronic hyperkeratosis
More informationRe-growing the Skeleton: Approaches in Tissue Engineering and Regenerative Medicine
Re-growing the Skeleton: Approaches in Tissue Engineering and Regenerative Medicine How we fix things now Total Knee Replacements Fracture Plates Fusing Joints Defining Regenerative Medicine restore form
More informationAnkle Replacement Surgery
Ankle Replacement Surgery Ankle replacement surgery is performed to replace the damaged articular surfaces of the three bones of the ankle joint with artificial implants. This procedure is now being preferred
More informationPlatelet Rich Plasma (PRP) injections. by Dr George Pitsis
Platelet Rich Plasma (PRP) injections by Dr George Pitsis Platelet Rich Plasma (PRP) injections have in the more recent years attracted significant attention as a clinical tools to assist with treatment
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): 7/1/2002 Most Recent Review Date (Revised): 3/24/2015 Effective Date: 11/2/2015 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Acellular dermal allografts for arthroplasty, 633 642 for plantar soft tissue augmentation, 543 555 Achilles tendon repair extracellular matrix
More informationBone Growth Stimulators AHM
Bone Growth Stimulators AHM Clinical Indications Ultrasonic osteogenesis stimulator (e.g., the Sonic Accelerated Fracture Healing System (SAFHS)) medically necessary DME to Ultrasonic osteogenesis stimulator
More informationRicardo E. Colberg, MD, RMSK. PM&R Sports Medicine Physician Andrews Sports Medicine and Orthopedic Center American Sports Medicine Institute
Ricardo E. Colberg, MD, RMSK PM&R Sports Medicine Physician Andrews Sports Medicine and Orthopedic Center American Sports Medicine Institute Pathophysiology of chronic orthopedic injuries Definition of
More informationFractures cause considerable
Clin Orthop Relat Res (2016) 474:1553 1559 / DOI 10.1007/s11999-016-4816-1 Clinical Orthopaedics and Related Research A Publication of The Association of Bone and Joint Surgeons Published online: 5 April
More informationREFERENCES for PLATELET RICH PLASMA (PRP)
REFERENCES for PLATELET RICH PLASMA (PRP) Daif ET. Autologous blood injection as a new treatment modality for chronic recurrent temporomandibular joint dislocation. Oral Surg Oral Med Oral Pathol Oral
More informationZUSAMMENSTELLUNG VON WISSENSCHAFTLICHEN PUBLIKATIONEN ZUR WIRKUNG DER PULSIERENDER MAGNETFELDTHERAPIE AUF KNOCHEN- UND KNORPELZELLEN
ZUSAMMENSTELLUNG VON WISSENSCHAFTLICHEN PUBLIKATIONEN ZUR WIRKUNG DER PULSIERENDER MAGNETFELDTHERAPIE AUF KNOCHEN- UND KNORPELZELLEN 1982 Effects of a pulsed electromagnetic field on a mixed chondroplastic
More informationUTILIZATION MANAGEMENT POLICY
TITLE: BONE GROWTH STIMULATORS EFFECTIVE DATE: July 1, 2015 UTILIZATION MANAGEMENT POLICY DOCUMENT HISTORY Original Endorsement Date: May, 1991 Subsequent Endorsement Date(s): 02/1992, 03/1994, 03/1995,
More informationINVISION Total Ankle Replacement System with PROPHECY Preoperative Navigation Revision of a Failed Agility Total Ankle Replacement
016625 REVISION R INVISION Total Ankle Replacement System with PROPHECY Preoperative Navigation Revision of a Failed Agility Total Ankle Replacement CASE STUDY Patient History The patient was a 65-year-old
More informationThe American Academy of Foot & Ankle Osteosynthesis. presents ADVANCED TECHNIQUES IN SKELETAL FIXATION OF THE FOOT AND ANKLE
The American Academy of Foot & Ankle Osteosynthesis presents ADVANCED TECHNIQUES IN SKELETAL FIXATION OF THE FOOT AND ANKLE Goodlett Farms Innovation Centre Memphis, Tennessee SCIENTIFIC CHAIRMAN John
More information